With over 1,000 beds and more than 10,000 employees, the University Medical Center Utrecht is one of the largest academic centers in the Netherlands. Patient care and biomedical research are closely linked, which creates an environment where scientific advancements quickly move from bench to bedside. Advancements that improve patients’ lives and that matter internationally. The scientific output from the UMC Utrecht has a 1.53 citation score between 1998 and 2009. This represents a scientific impact 53% higher than world average. The faculty of medicine from UtrechtUniversity, which transferred five degree programs to UMC Utrecht, comprises over 3,500 bachelor and master students in medicine, biomedical sciences and clinical health sciences. The University Medical Center Utrecht finds itself in the middle of a vibrant biomedical research community: Utrecht Life Sciences. This represents a strategic alliance in education, research and entrepreneurship in the domain of the life sciences in the Utrecht area, located in the very heart of the Netherlands. Within Utrecht Life Sciences all Master’s and PhD programmes are combined in the Graduate School of Life Sciences. The ‘ UtrechtSciencePark’ houses twenty smaller and several larger spin off
companies. Other members of the alliance include UtrechtUniversity, the Hubrecht Institute, the University of Applied Sciences Utrecht, the National Institute for Public Health and the Environment and the companies Genmab and Danone. The UMC Utrecht has concentrated its research efforts in six programs, with the diagnosis and treatment of respiratory tract infections having been identified as key target diseases in 2 programs, Child Health and Infection & Immunity.
Prof. Louis Bont
Louis Bont is a Paediatric Infectious Diseases and Immunology specialist at the University Medical Center Utrecht, The Netherlands. He leads the Utrecht RSV Research Group and the Dutch RSV Neonatal Network.
His research focuses on the clinical, genetic and immunological determinants of RSV bronchiolitis. He is the principle investigator of a number of large well-defined RSV cohorts providing insight into the immunopathogenesis of RSV infection. He has a strong interest in the relationship between RSV bronchiolitis and the development of long-term airway morbidity, including asthma. He is the principle investigator of 2 investigator initiated studies aiming to prevent RSV-related long-term airway disease. He has led a placebo controlled trial establishing the of RSV prophylaxis by palivizumab on recurrent wheeze in otherwise healthy late preterm infants. His basic research focuses on the development of new therapeutics using animal models. He has published 85 papers in peer-reviewed journals.
He studied medicine at the AmsterdamMedicalCenter, The Netherlands (1990-1996). He followed the Pediatric residency program (2001-2006) and a Pediatric Infectious Diseases Fellowship (2006-2008) at the University Medical Center Utrecht. Dr. Bont received his Ph.D. in 2001 at the University Medical Center Utrecht.